Important Information for Investors of ESSA Pharma Inc.:
On March 17, 2025, Rosen Law Firm, a leading investor rights law firm, issued a press release reminding purchasers of securities of ESSA Pharma Inc. (NASDAQ: EPIX) between December 12, 2023, and October 31, 2024, inclusive (the “Class Period”), of the significant March 25, 2025 lead plaintiff deadline in a securities class action lawsuit.
Background:
ESSA Pharma is a clinical-stage biotechnology company focused on developing and commercializing novel therapeutics for the treatment of rare and debilitating diseases. The company’s lead product candidate, EPI-589, is a selective and potent androgen receptor antagonist being developed for the treatment of prostate cancer.
The Lawsuit:
The lawsuit alleges that ESSA Pharma made false and/or misleading statements and/or failed to disclose: (1) that EPI-589’s clinical trial data was insufficient to support the company’s claims that it could be developed as a treatment for prostate cancer; (2) that ESSA Pharma’s clinical trials for EPI-589 were not progressing as planned; and (3) that as a result of the foregoing, defendants’ positive statements about the company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Implications for Investors:
If you purchased ESSA Pharma securities during the Class Period and have suffered a loss, you may be entitled to compensation. The lead plaintiff deadline for this lawsuit is March 25, 2025. To learn more about the case or join the action, contact the Rosen Law Firm.
Impact on the World:
The outcome of this lawsuit could have significant implications for the biotechnology industry and investors. If the allegations are proven true, it could lead to increased scrutiny of clinical trial data and reporting by biotech companies. This, in turn, could result in increased transparency and accountability, ultimately benefiting investors and patients.
Conclusion:
The Rosen Law Firm’s press release serves as a reminder for investors to be vigilant when investing in biotechnology companies and to closely monitor the progress of clinical trials. The outcome of this lawsuit could have far-reaching implications for the industry and investors. If you believe you may be entitled to compensation, contact the Rosen Law Firm before the lead plaintiff deadline.
- Rosen Law Firm reminds investors of ESSA Pharma securities purchased between December 12, 2023, and October 31, 2024, of the March 25, 2025 lead plaintiff deadline in a securities class action lawsuit.
- The lawsuit alleges that ESSA Pharma made false and/or misleading statements regarding the progress of clinical trials for its lead product candidate, EPI-589.
- The outcome of this lawsuit could lead to increased scrutiny of clinical trial data and reporting by biotech companies, ultimately benefiting investors and patients.
